Segmental Reporting (Tables)

9 Months Ended

Sep. 30, 2015

Segment Reporting [Abstract]

Schedule of Segment Revenue from Major Products

9 months to	September 30,	September 30,
	2015	2014
	$’M	$’M
	___________	___________
VYVANSE	1,268.9	1,065.6
CINRYZE	474.4	360.6
LIALDA/MEZAVANT	483.0	449.1
ELAPRASE	405.5	449.5
FIRAZYR	319.8	262.3
REPLAGAL	325.5	380.7
PENTASA	232.7	213.8
VPRIV	256.2	273.0
ADDERALL XR	259.7	280.2
FOSRENOL	132.9	136.2
GATTEX/REVESTIVE	95.2	-
XAGRID	75.0	82.1
INTUNIV	45.0	279.0
NATPARA	12.8	-
Other product sales	89.6	97.6
	____________	____________
Total product sales	4,476.2	4,329.7
	____________	____________